Kiora Pharmaceuticals Receives Composition-of-Matter Patent for KIO-104

Introduction

Encinitas, California–(Newsfile Corp. – February 13, 2025) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition-of-matter patent (US-12209073-B2) on a specific crystalline form, or polymorph, of KIO-104. KIO-104 is a novel, non-steroidal anti-inflammatory, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

Overview of KIO-104

KIO-104 is a groundbreaking new medication developed by Kiora Pharmaceuticals that targets dihydroorotate dehydrogenase (DHODH), an enzyme involved in the synthesis of pyrimidines. By inhibiting DHODH, KIO-104 has shown promising results in preclinical studies as a potent anti-inflammatory agent.

Composition-of-Matter Patent

The issuance of a composition-of-matter patent for the specific crystalline form of KIO-104 is a significant milestone for Kiora Pharmaceuticals. This patent provides legal protection for the unique chemical structure of KIO-104, ensuring that the company has exclusive rights to manufacture and sell this novel medication.

With this patent in place, Kiora Pharmaceuticals can now move forward with the development and commercialization of KIO-104, bringing a new treatment option to patients suffering from inflammatory conditions.

Impact on Individuals

For individuals, the availability of KIO-104 could potentially offer a new and effective treatment option for various inflammatory diseases. This medication has the potential to improve the quality of life for patients by providing relief from symptoms and reducing inflammation in the body.

Impact on the World

On a larger scale, the development of KIO-104 and the issuance of its composition-of-matter patent represent significant advancements in the field of drug discovery and development. This innovative medication could pave the way for new treatments for inflammatory conditions and inspire further research in the area of DHODH inhibition.

Conclusion

In conclusion, the issuance of the composition-of-matter patent for KIO-104 marks a major achievement for Kiora Pharmaceuticals and opens up new possibilities for the treatment of inflammatory diseases. This groundbreaking medication has the potential to make a positive impact on individuals’ lives and contribute to advancements in the pharmaceutical industry.